Clinical trials
Tolerance clinical trials
Below are recruiting tolerance clinical trials, each written for real people, not researchers. We’re tracking 942 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07377539RecruitingPhase 1
A study of JZP047 in healthy volunteers
This study tests a new investigational drug called JZP047 in healthy volunteers. Researchers want to see how safe it is, how the body processes it, and whether taking it with food changes its effects.
Lincoln, NebraskaAges 18–55 - NCT07377175RecruitingPhase 1
Safety study of BSY001 in healthy adults
This early-phase trial tests a single or multiple doses of BSY001 to see if it is safe and how the body handles it. It is for healthy volunteers aged 18 to 50 who are not allergic to similar drugs and can avoid certain medicines and activities during the study.
HangzhouAges 18–50 - NCT07376642RecruitingEarly Phase 1
Testing IMV101 for relapsed B-cell lymphoma
This study tests an experimental drug called IMV101 for people with certain types of B-cell non-Hodgkin lymphoma that have come back or not responded to other treatments. It aims to see if the drug is safe and if it can shrink tumors.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07371455RecruitingPhase 1
LWP779 safety trial for healthy volunteers
This trial tests a new oral medication called LWP779 in healthy adults to see if it is safe and how the body processes it. It helps determine the right dose for future studies.
AdelaideAges 18–65 - NCT07372703RecruitingPhase 1
Safety study of VV913 capsules in healthy Chinese men
This study tests a new capsule called VV913 in healthy male volunteers to see how safe it is and how the body processes it. It is a first-in-human trial in China to gather basic safety information.
Hefei, AnhuiAges 18–45 - NCT07371065Enrolling by invitationPhase 1
Testing a new drug's safety in healthy adults
This trial tests a new medicine called LY03021 in healthy volunteers to see how safe it is, how the body processes it, and if food changes its effects. It's for people who are generally healthy and not taking other medications.
ShanghaiAges 18–45 - NCT06842108Recruiting
Blood flow and heart-lung fitness in type 2 diabetes
This study looks at how blood flow changes (hemodynamics) affect your heart and lung fitness (cardiopulmonary fitness) in people with type 2 diabetes. It may help doctors understand how diabetes affects the heart and lungs.
Karachi, SindhAges 30–50 - NCT05989958RecruitingPhase 1/Phase 2
HepaCure for acute-on-chronic liver failure
This trial tests a new treatment called HepaCure for people with acute-on-chronic liver failure (a sudden worsening of liver function in someone with long-term liver disease). The goal is to see if it is safe and can help improve liver function.
Beijing, Beijing MunicipalityAges 18–65 - NCT07368803RecruitingPhase 1/Phase 2
Personalized mRNA vaccine for bile duct cancer after surgery
This trial tests a personalized mRNA vaccine (iNeo-Vac-R01) made from your tumor's unique markers to help prevent cancer from coming back after surgery for bile duct or other digestive cancers. It may be an option if standard treatments have stopped working or caused side effects.
Hangzhou, ZhejiangAges 18–75 - NCT07368153RecruitingPhase 2
Preventing EBV infection after kidney transplant
This trial tests if an experimental drug can prevent a common virus (EBV) from causing problems in people who receive a kidney from an EBV-positive donor but have never been exposed to EBV themselves. It aims to reduce the risk of transplant-related complications.
Bern, Canton of BernAges 18 years+ - NCT07366658RecruitingPhase 1
Experimental therapy for neuroendocrine tumors that did not respond to treatment
This trial tests an experimental therapy (NEUK203-13) for people with neuroendocrine tumors, including small cell lung cancer, that have not responded to or stopped responding to standard treatments. It aims to see if the drug is safe and to look for early signs that it might shrink tumors, especially in people whose tumors have a specific marker called DLL3.
BeijingAges 18–75 - NCT07366866RecruitingPhase 1
Safety study of an experimental drug in healthy adults
This trial tests a new drug, GenSci136, in healthy adults to see if it's safe and how the body processes it. If you qualify, you would receive the drug and be monitored for side effects.
Shanghai, Shanghai MunicipalityAges 18–45 - NCT07366034RecruitingPhase 3
Testing nerandomilast for children with lung scarring
This trial tests a new oral medicine, nerandomilast, to see if it helps children and teens (ages 2 to under 18) who have a type of lung disease that causes scarring (interstitial lung disease). The study monitors how well patients tolerate the drug and whether it improves their breathing.
Los Angeles, CaliforniaAges 2–17 - NCT07369154RecruitingPhase 3
Long-term safety study of an investigational schizophrenia medication
This study is testing how safe and tolerable an investigational medication is over the long term (52 weeks) when added to your current antipsychotic treatment. It's for people with schizophrenia whose symptoms are stable, and it aims to see if the new medication can help without causing serious side effects.
Chandler, ArizonaAges 18–65 - NCT07363967RecruitingPhase 1
Study of SWA1211 for advanced solid tumors
This trial tests a new oral drug, SWA1211, for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if it is safe and works against the cancer.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07363395RecruitingPhase 1
A study of ASCT-83 in healthy adults
This trial tests a new medication called ASCT-83 in healthy adults to see how safe it is and how the body processes it. It may help researchers understand the right dose for future studies.
Saint Paul, MinnesotaAges 18–64 - NCT07368478RecruitingPhase 1
Study of BC2027 for advanced solid tumors with GPC3
This trial tests a new drug called BC2027 for people with advanced solid tumors that have a protein called GPC3. If standard treatments have stopped working, are not available, or caused side effects, this study may offer a new option.
Shanghai, Shanghai, ChinaAges 18 years+ - NCT07362459RecruitingPhase 3
Study of SCTB14 for untreated advanced non-small cell lung cancer
This trial tests a new drug, SCTB14, as a first treatment for advanced non-small cell lung cancer that has a high level of PD-L1. It aims to see if the drug is safe and effective for people who haven't had other treatments for their cancer.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07365462RecruitingPhase 2
Study of NBI-1065890 for tardive dyskinesia in adults
This trial tests whether an oral medication, NBI-1065890, can reduce the involuntary muscle movements caused by long-term use of antipsychotic drugs. It is for adults with moderate to severe tardive dyskinesia who also have a stable mental health condition like schizophrenia or bipolar disorder.
Bryant, ArkansasAges 18–75 - NCT07359066RecruitingPhase 1/Phase 2
SPR1020 for advanced solid tumors with DNA repair defects
This trial tests an experimental drug (SPR1020) for people with advanced solid tumors that have not responded to standard treatments, especially those with BRCA or related gene mutations. The drug is taken by mouth and the study aims to find the right dose and see if it helps shrink tumors.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07358377RecruitingPhase 1
Combination therapy for HR-positive, HER2-negative cancer
This trial tests a new drug, HRS-6209, combined with other treatments for people with hormone receptor-positive, HER2-negative cancer. The goal is to see if the combination is safe and works well.
Bowral, New South WalesAges 18 years+ - NCT07355270Recruiting
Radiofrequency vapor ablation for type 2 diabetes
This trial tests a new device that uses radiofrequency energy to treat the lining of the upper small intestine in people with type 2 diabetes. The goal is to see if this treatment is safe and helps improve blood sugar control.
Scottsdale, ArizonaAges 22–65 - NCT07358195RecruitingEarly Phase 1
Combined stem cell and kidney transplant from a relative
This trial tests a combined transplant of blood-forming stem cells and a kidney from the same family member. It aims to help people with both advanced kidney failure and a blood cancer by potentially reducing the need for lifelong anti-rejection medicines.
Boston, MassachusettsAges 18–70 - NCT07361237RecruitingPhase 1
HJ-004-02 tablet for EGFR-mutated lung cancer
This early-phase trial tests a once-daily tablet (HJ-004-02) for people with a specific type of lung cancer that has an EGFR mutation. It aims to see if the drug is safe and if it can shrink tumors when other treatments have stopped working.
Shanghai, Shanghai MunicipalityAges 18–75
Hear when a new Tolerance trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for tolerance?
- Yes. Clin2 currently lists 942 recruiting tolerance studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a tolerance trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a tolerance trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.